A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study

C. Jessup, G. Reyes, A. Fothergill, D. McCarthy, M. Rinaldi, S. Messer, M. Pfaller, M. Ghannoum

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A comparative study of conventional amphotericin B, Abelcet and AmBisome was performed using a microdilution format of the NCCLS M27-A methodology for susceptibility testing against 300 fungal isolates (152 yeasts, 148 filamentous fungi) in both RPMI-1640 and antibiotic medium 3 (AB3). The clinical isolates included Candida albicans (n=54), Candida glabrata (n=25), Candida parapsilosis (n=23), Candida krusei (n=19), Candida lusitaniae (n=14), Cryptococcus neoformans (n=5), Candida tropicalis (n=12), Aspergillus flavus (n=34), Aspergillus fumigatus (n=46) and 68 other filamentous fungi encompassing 22 different genera. The minimal inhibitory concentrations (MIC) for all drugs were defined as the lowest concentrations in which there was no visible growth. MICs were determined after 48 h for yeasts and 72 h for filamentous fungi. The mean MICs ± standard error (μg/ml) for yeasts and filamentous fungi, respectively, were: Abelcet, 0.51 ± 0.21, 4.34 ± 0.61; AmBisome, 1.28 ± 0.24, 5.68 ± 0.57; amphotericin B, 0.29 ± 0.11, 1.12 ± 0.19, respectively. Overall, against both yeasts and filamentous fungi Abelcet proved to have more potent antifungal activity than AmBisome. Using AB3 as opposed to RPMI-1640 generally produced lower MIC values but did not have any effect on the order of relative activity with all of the antifungal agents tested. In conclusion, our data shows that Abelcet is more active than AmBisome against pathogenic yeast and filamentous fungi when assayed in AB3 in vitro. Comparison of the activities of these antifungals in experimental animal models is necessary to determine whether these in vitro findings are correlated with in vivo efficacy.

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalJournal of Chemotherapy
Volume12
Issue number1
StatePublished - 2000

Fingerprint

Amphotericin B
Multicenter Studies
Head
Lipids
Fungi
Yeasts
Candida
Anti-Bacterial Agents
Candida tropicalis
Candida glabrata
Aspergillus flavus
Cryptococcus neoformans
Aspergillus fumigatus
In Vitro Techniques
liposomal amphotericin B
Antifungal Agents
Candida albicans
Animal Models
Growth
Pharmaceutical Preparations

Keywords

  • Abelcet
  • AmBisome
  • Antifungals
  • In vitro susceptibility
  • Lipid-based amphotericin B

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Jessup, C., Reyes, G., Fothergill, A., McCarthy, D., Rinaldi, M., Messer, S., ... Ghannoum, M. (2000). A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study. Journal of Chemotherapy, 12(1), 22-29.

A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B : A multicenter study. / Jessup, C.; Reyes, G.; Fothergill, A.; McCarthy, D.; Rinaldi, M.; Messer, S.; Pfaller, M.; Ghannoum, M.

In: Journal of Chemotherapy, Vol. 12, No. 1, 2000, p. 22-29.

Research output: Contribution to journalArticle

Jessup, C, Reyes, G, Fothergill, A, McCarthy, D, Rinaldi, M, Messer, S, Pfaller, M & Ghannoum, M 2000, 'A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study', Journal of Chemotherapy, vol. 12, no. 1, pp. 22-29.
Jessup, C. ; Reyes, G. ; Fothergill, A. ; McCarthy, D. ; Rinaldi, M. ; Messer, S. ; Pfaller, M. ; Ghannoum, M. / A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B : A multicenter study. In: Journal of Chemotherapy. 2000 ; Vol. 12, No. 1. pp. 22-29.
@article{088ee7d6bf4b4dd58ab476736641ac06,
title = "A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study",
abstract = "A comparative study of conventional amphotericin B, Abelcet and AmBisome was performed using a microdilution format of the NCCLS M27-A methodology for susceptibility testing against 300 fungal isolates (152 yeasts, 148 filamentous fungi) in both RPMI-1640 and antibiotic medium 3 (AB3). The clinical isolates included Candida albicans (n=54), Candida glabrata (n=25), Candida parapsilosis (n=23), Candida krusei (n=19), Candida lusitaniae (n=14), Cryptococcus neoformans (n=5), Candida tropicalis (n=12), Aspergillus flavus (n=34), Aspergillus fumigatus (n=46) and 68 other filamentous fungi encompassing 22 different genera. The minimal inhibitory concentrations (MIC) for all drugs were defined as the lowest concentrations in which there was no visible growth. MICs were determined after 48 h for yeasts and 72 h for filamentous fungi. The mean MICs ± standard error (μg/ml) for yeasts and filamentous fungi, respectively, were: Abelcet, 0.51 ± 0.21, 4.34 ± 0.61; AmBisome, 1.28 ± 0.24, 5.68 ± 0.57; amphotericin B, 0.29 ± 0.11, 1.12 ± 0.19, respectively. Overall, against both yeasts and filamentous fungi Abelcet proved to have more potent antifungal activity than AmBisome. Using AB3 as opposed to RPMI-1640 generally produced lower MIC values but did not have any effect on the order of relative activity with all of the antifungal agents tested. In conclusion, our data shows that Abelcet is more active than AmBisome against pathogenic yeast and filamentous fungi when assayed in AB3 in vitro. Comparison of the activities of these antifungals in experimental animal models is necessary to determine whether these in vitro findings are correlated with in vivo efficacy.",
keywords = "Abelcet, AmBisome, Antifungals, In vitro susceptibility, Lipid-based amphotericin B",
author = "C. Jessup and G. Reyes and A. Fothergill and D. McCarthy and M. Rinaldi and S. Messer and M. Pfaller and M. Ghannoum",
year = "2000",
language = "English (US)",
volume = "12",
pages = "22--29",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "1",

}

TY - JOUR

T1 - A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B

T2 - A multicenter study

AU - Jessup, C.

AU - Reyes, G.

AU - Fothergill, A.

AU - McCarthy, D.

AU - Rinaldi, M.

AU - Messer, S.

AU - Pfaller, M.

AU - Ghannoum, M.

PY - 2000

Y1 - 2000

N2 - A comparative study of conventional amphotericin B, Abelcet and AmBisome was performed using a microdilution format of the NCCLS M27-A methodology for susceptibility testing against 300 fungal isolates (152 yeasts, 148 filamentous fungi) in both RPMI-1640 and antibiotic medium 3 (AB3). The clinical isolates included Candida albicans (n=54), Candida glabrata (n=25), Candida parapsilosis (n=23), Candida krusei (n=19), Candida lusitaniae (n=14), Cryptococcus neoformans (n=5), Candida tropicalis (n=12), Aspergillus flavus (n=34), Aspergillus fumigatus (n=46) and 68 other filamentous fungi encompassing 22 different genera. The minimal inhibitory concentrations (MIC) for all drugs were defined as the lowest concentrations in which there was no visible growth. MICs were determined after 48 h for yeasts and 72 h for filamentous fungi. The mean MICs ± standard error (μg/ml) for yeasts and filamentous fungi, respectively, were: Abelcet, 0.51 ± 0.21, 4.34 ± 0.61; AmBisome, 1.28 ± 0.24, 5.68 ± 0.57; amphotericin B, 0.29 ± 0.11, 1.12 ± 0.19, respectively. Overall, against both yeasts and filamentous fungi Abelcet proved to have more potent antifungal activity than AmBisome. Using AB3 as opposed to RPMI-1640 generally produced lower MIC values but did not have any effect on the order of relative activity with all of the antifungal agents tested. In conclusion, our data shows that Abelcet is more active than AmBisome against pathogenic yeast and filamentous fungi when assayed in AB3 in vitro. Comparison of the activities of these antifungals in experimental animal models is necessary to determine whether these in vitro findings are correlated with in vivo efficacy.

AB - A comparative study of conventional amphotericin B, Abelcet and AmBisome was performed using a microdilution format of the NCCLS M27-A methodology for susceptibility testing against 300 fungal isolates (152 yeasts, 148 filamentous fungi) in both RPMI-1640 and antibiotic medium 3 (AB3). The clinical isolates included Candida albicans (n=54), Candida glabrata (n=25), Candida parapsilosis (n=23), Candida krusei (n=19), Candida lusitaniae (n=14), Cryptococcus neoformans (n=5), Candida tropicalis (n=12), Aspergillus flavus (n=34), Aspergillus fumigatus (n=46) and 68 other filamentous fungi encompassing 22 different genera. The minimal inhibitory concentrations (MIC) for all drugs were defined as the lowest concentrations in which there was no visible growth. MICs were determined after 48 h for yeasts and 72 h for filamentous fungi. The mean MICs ± standard error (μg/ml) for yeasts and filamentous fungi, respectively, were: Abelcet, 0.51 ± 0.21, 4.34 ± 0.61; AmBisome, 1.28 ± 0.24, 5.68 ± 0.57; amphotericin B, 0.29 ± 0.11, 1.12 ± 0.19, respectively. Overall, against both yeasts and filamentous fungi Abelcet proved to have more potent antifungal activity than AmBisome. Using AB3 as opposed to RPMI-1640 generally produced lower MIC values but did not have any effect on the order of relative activity with all of the antifungal agents tested. In conclusion, our data shows that Abelcet is more active than AmBisome against pathogenic yeast and filamentous fungi when assayed in AB3 in vitro. Comparison of the activities of these antifungals in experimental animal models is necessary to determine whether these in vitro findings are correlated with in vivo efficacy.

KW - Abelcet

KW - AmBisome

KW - Antifungals

KW - In vitro susceptibility

KW - Lipid-based amphotericin B

UR - http://www.scopus.com/inward/record.url?scp=0034105811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034105811&partnerID=8YFLogxK

M3 - Article

C2 - 10768512

AN - SCOPUS:0034105811

VL - 12

SP - 22

EP - 29

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 1

ER -